

30th July, 2024

BSE Limited
P.J. Towers, Dalal Street, Fort,
Mumbai- 400 001
BSE scrip code: 543635

National Stock Exchange of India Limited
Exchange Plaza, Bandra-Kurla Complex,
Bandra (East), Mumbai – 400 051
NSE symbol: PPLPHARMA

Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”) – Sale of Company’s Unit situated at Thane

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI Listing Regulations, we wish to inform you that the Administrative Committee of the Board of Directors of the Company at its meeting held today i.e. 30th July, 2024 granted its approval for sale of Company’s unit comprising of a plot of land and factory premises situated at A-159, MIDC, Wagle Industrial Estate, Thane West - 400604 (“Transaction”) to Sankalpan Architects Private Limited (“Buyer”), for a proposed consideration of Rs. 9 Crores approx. and for execution of a Memorandum of Understanding with the Buyer.

The Transaction is expected to be completed within 6 months, upon execution of definitive documents basis the terms & conditions thereof.

The aforementioned Company’s unit is decommissioned and the sale has no impact on the operations of the Company. The details pertaining to amount and percentage of the turnover or revenue or income and net worth contributed by the unit during the last financial year is Nil.

Further, the Buyer does not belong to the promoter/promoter group/group companies and the Transaction does not fall under the ambit of Related Party Transaction.

Kindly take the above on record and oblige.

Thank you,

Yours truly,

For Piramal Pharma Limited

Tanya Sanish
Company Secretary

Piramal Pharma Limited

CIN: L24297MH2020PLC338592

Registered Office: Gr. Flr. Piramal Ananta, Agastya Corporate Park, Opp Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai – 400070 India
T: +91 22 3802 3000 / 4000; Email: shareholders.ppl@piramal.com

piramalpharma.com